Afinitor (Everolimus) Patent Expiration, LOE Window & CMS Spending

Afinitor (Everolimus) by Novartis: FDA Orange Book LOE 2028-07-01, 13 AB generics, $53.5M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN022334 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-07-01
Orange Book Patents (*PED Extensions)3 patents (1 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$53.5M
2024 Medicare Part D Spend$17.7M
2024 Medicaid Spend$35.7M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 18.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.